Date: 2015-06-25
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Novo Nordisk (Denmark)
Product: OI320GT (NN1957)
Action
mechanism: insulin analogue. OI320GT(NN1957) is a long-acting oral basal insulin analogue.
Disease: type 2 diabetes
Therapeutic area: Metabolic diseases
Country: Germany
Trial
details: This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of insulin 320 in healthy subjects. (NCT02479022)
Latest
news:
